AstraZeneca Diligence Clause Samples
The "AstraZeneca Diligence" clause requires AstraZeneca to exercise a specified level of effort, often termed as "commercially reasonable diligence," in fulfilling its obligations under an agreement, such as developing, manufacturing, or commercializing a product. In practice, this means AstraZeneca must actively pursue the agreed objectives, allocate appropriate resources, and make decisions consistent with how similar companies would act under comparable circumstances. This clause ensures that AstraZeneca cannot neglect its responsibilities and provides assurance to the other party that the project or collaboration will be pursued with genuine effort and commitment.
AstraZeneca Diligence. AstraZeneca shall use Commercially Reasonable Efforts to conduct the AstraZeneca Research Activities set forth in each Annual Research Plan, if any.
AstraZeneca Diligence. Commencing on (i) the Effective Date, with respect to STAT3 Products and [***] Products licensed to AstraZeneca under Section 6.1.1 and Section 6.1.2, and (ii) on an Oncology Target-by-Oncology Target and Product-by-Product basis, the date Isis grants AstraZeneca the license under Section 6.1.3 related to such Oncology Target, except for the Isis Conducted Activities that do not involve Additional Plan Costs, AstraZeneca is solely responsible for all Development, Manufacturing and Commercialization activities, and for all costs and expenses associated therewith, with respect to the Development, Manufacture and Commercialization of Products.
AstraZeneca Diligence. On a Collaboration Target-by-Collaboration Target basis, commencing on the Collaboration Program Exercise Date, except as expressly provided otherwise in this Agreement, AstraZeneca is solely responsible for the Development, Manufacture and Commercialization of Products with respect to such Collaboration Target, and will be solely responsible for all costs associated therewith. With respect to each Licensed Program, AstraZeneca will use Commercially Reasonable Efforts (i) to Develop a Product and to seek Approval for such Product for use in humans [***], (ii) following Approval, to Commercialize such Product for use in humans [***], (iii) to Develop and Commercialize a Product for use in humans worldwide (outside of [***]) to the extent consistent with the global commercialization strategy and efforts AstraZeneca would use for AstraZeneca’s similar products in the same franchise, and (iv) to Develop and Commercialize each Product substantially in accordance with the applicable IPP.
AstraZeneca Diligence. On a Licensed Program-by-Licensed Program basis, (a) with respect to the Collaboration Products, commencing on the Collaboration Program Exercise Date for the applicable Collaboration Product, and (b) with respect to the [***] Products, commencing on the Fourth Amendment Effective Date, except as expressly provided otherwise in this Agreement, AstraZeneca is solely responsible for the Development, Manufacture and Commercialization of the Collaboration Products and the [***] Products, and will be solely responsible for all costs associated therewith. With respect to each Licensed Program, AstraZeneca will use Commercially Reasonable Efforts (i) to Develop a Product and to seek Approval for such Product for use in humans [***], (ii) following Approval, to Commercialize such Product for use in humans [***], (iii) to Develop and Commercialize a Product for use in humans worldwide (outside of [***]) to the extent consistent with the global commercialization strategy and efforts AstraZeneca would use for AstraZeneca’s similar products in the same franchise, and (iv) to Develop and Commercialize each Product substantially in accordance with the applicable IPP.” e. Section 5.1.1. The first sentence of Section 5.1.1 (Specific Performance Milestone Events) is hereby deleted in its entirety and replaced with the following: